Tuberculosis Clinical Registry in Europe

Condition(s) studied

Investigational drug(s) / intervention(s)

data collection: Prospective data collection in a clinical data registry

Study summary

The TBnet registry is a multinational, prospective tuberculosis registry established by the Tuberculosis Network European Trialsgroup (TBnet e.V.) to collect and analyze long-term data from TB patients across Europe. Its purpose is to centralize data on TB epidemiology, prevention, diagnosis, and treatment to improve care, support research, and ultimately help eliminate TB. The registry captures risk factors, diagnostic details (e.g., microbiology, imaging, drug resistance), treatment data, side effects, outcomes, and late complications.

Eligibility

Primary outcome measure(s)

• Extrapulmonary TB: Favourable treatment outcome — December 2040
  Identification of parameters that predict/are significantly associated with favorable outcome in EPTB
• Drug-resistant TB: Description of treatment outcome — December 2040
  Percentage of patients cured, failed, died, under/after therapy according to WHO and TBnet outcome criteria
• Drug-resistant TB: Description of treatment completion — December 2040
  Percentage of patients who develop serious/severe drug-related adverse events/who have to change regimen due to drug-related adverse events
• Drug-susceptible TB: Mortality risk score — December 2040
  Development of a TB mortality risk score, defined by a final set of predictors and a weighted scoring system based on routine clinical, radiological, microbiological, and laboratory data.
• Therapeutic drug monitoring: Description of Pharmacokinetics — December 2040
  Summary of pharmacokinetic parameters: Mean max/min concentrations, number of patients that are over-/under-/correctly dosed

Trial sites (2)

More Research Center Borstel trials in Germany

Other trials for the same condition